AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe
Is AstraZeneca (LSE:AZN) Reasonable After Its Oncology Led Cash Flow Push?
AstraZeneca (LSE:AZN) Will Transfer Its Primary Listing To The NYSE In 2026
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
AstraZeneca Reportedly Eliminates 600 US Sales Positions To Fund Pipeline
AstraZeneca cuts 600 US jobs amid $1.5B cost-saving overhaul - Bloomberg
'AstraZeneca Cuts 600 US Sales Staff as Savings Drive Kicks In'- Bloomberg
AstraZeneca's Baxfendy Recommended For Approval In EU For Treatment Of Adult Patients Arterial Hypertension Insufficiently Controlled With At Least Two Antihypertensive Medicinal Products
AstraZeneca acquires bacterial vaccine biotech, Omniose
AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline
AstraZeneca (LSE:AZN) Reaffirms Guidance As Pipeline Strength Keeps Undervaluation In View
AstraZeneca (LSE:AZN) Stock Fair Value Edges Higher After Mixed Analyst Target Changes
AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
AstraZeneca Acquires Omniose; Financial Terms Not Disclosed
AstraZeneca (NYSE:AZN) Stands Out for Dividend Quality and Sustainable Payout
'AstraZeneca Made $10 Billion Offer For Rhythm Pharmaceuticals; Rhythm Specializes In Treatments For Metabolic Conditions And Severe Obesity' - WSJ Exclusive
AstraZeneca (LSE:AZN) Filing Acceptance In Europe And Japan Puts Lung Cancer Combo Forward
AstraZeneca results reassure on long-term growth as three brokers raise price targets
AstraZeneca Analyst Raises Price Target On Q3 Results, Shift In Avanzar Timing
AstraZeneca: 3 Key Takeaways for Long-Term Investors
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.